Galectin Therapeutics Inc logo

Galectin Therapeutics Inc

$ 1.66 0 (0%) 10:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 98.60M
Enterprise V:
$ 106.27M
Volume:
35.20K
Avg Vol (2M):
54.41K
Also Trade In:
Volume:
35.20K
Market Cap $:
98.60M
PE Ratio:
At Loss
Avg Vol (2-Month):
54.41K
Enterprise Value $:
106.27M
PB Ratio:
0
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Name Current Vs Industry Vs History
Cash-To-Debt 0.82
Equity-to-Asset -0.59
Debt-to-Equity -1.95
Debt-to-EBITDA -0.86
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -14.2
3-Year EPS without NRI Growth Rate -11
3-Year FCF Growth Rate -17.2
Name Current Vs Industry Vs History
5-Day RSI 49.72
9-Day RSI 44.66
14-Day RSI 43.79
6-1 Month Momentum % 11.8
12-1 Month Momentum % -51.22

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.37
Quick Ratio 2.37
Cash Ratio 2.22

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -12.9
Name Current Vs Industry Vs History
ROE % -2342.23
ROA % -102.12
ROIC % -6152.48
ROC (Joel Greenblatt) % -52671.25
ROCE % -133.56

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT -3.08
EV-to-EBITDA -3.08
EV-to-FCF -3.88
Earnings Yield (Greenblatt) % -32.36

Financials (Next Earnings Date:2022-11-15 Est.)

GALT's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:GALT

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -0.59
Beta 1.54
Volatility % 87.82
14-Day RSI 43.79
14-Day ATR ($) 0.124116
20-Day SMA ($) 1.7225
12-1 Month Momentum % -51.22
52-Week Range ($) 1.19 - 3.78
Shares Outstanding (Mil) 59.4

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Galectin Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Galectin Therapeutics Inc Analysis

Share your research

Headlines

See More
No news.